IP Library › Granted Patent US 10,093,711
Granted Patent B2
US 10,093,711 · App. 15/371,131 · Granted Oct 9, 2018

Interleukin-2 muteins for the expansion of T-regulatory cells

Inventor: Gunasekaran Kannan (Daly City, CA)
Assignee: Amgen Inc.
C07K14/55C07K16/00A61K38/00C07K2317/41C07K2317/52C07K2317/524C07K2317/71C07K2317/94C07K2319/21C07K2319/30C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,093,711
App. No.
15/371,131
Granted
Oct 9, 2018
Kind
B2
Abstract

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

Claims (5)

1. A Fc-fusion protein comprising the Fc region of a human IgG1 antibody wherein said Fc region comprises a N297G mutation and one or more substitutions of the amino acid sequence set forth in SEP ID NO:3 at position V259, A287, R292, V302, L306, V323, or I332 with a cysteine amino acid residue, using EU numbering scheme, further comprising a deletion of the C-terminal lysine residue, and wherein said Fc region of a human IgG1 comprises at least 95% identity to the amino acid sequence set forth in SEQ ID NO:3.

2. The Fc-fusion protein of claim 1 , wherein said Fc region comprises an A287C and L306C substitution within the amino acid sequence set forth in SEQ ID NO:3.

3. The Fc-fusion protein of claim 1 , wherein said Fc region comprises a V259C and L306C substitution within the amino acid sequence set forth in SEQ ID NO:3.

4. The Fc-fusion protein of claim 1 , wherein said Fc region comprises a R292C and V302C substitution within the amino acid sequence set forth in SEQ ID NO:3.

5. The Fc-fusion protein of claim 1 , wherein said Fc region comprises a V323C and I332C substitution within the amino acid sequence set forth in SEQ ID NO:3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: GAVIN, MARC A.; KANNAN, GUNASEKARAN; LI, LI; PEARSON, JOSHUA T.; KAROW, MARGARET
To: AMGEN INC.
Reel/Frame 044860/0188 →
Continuity (3)
Division 14209914 · Mar 13, 2014
Provisional Application 61784669 · Mar 14, 2013
Related Publication 20170081382A1 · Mar 23, 2017
Cited By (5)
US 50,550 US 12,297,249 US 12,303,567 US 12,642,840 US 12,734,215